Phase 1, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib in adult subjects

Authors
Category Primary study
JournalCancer Research
Year 2023
This article has no abstract
Epistemonikos ID: 5dfdbfb256b898353bf3b5603b72c4d96185861c
First added on: Feb 16, 2025